Dupilumab

The TRials with EblasaKimab in Dupilumab eXperienced atopic dermatitis patients (TREK-DX) study will evaluate eblasakimab in a patient population with few safe treatment optionsThe study…

NASHVILLE, Tenn. -- Treatment with the biologic dupilumab (Dupixent) was associated with sustained reductions in oral…

The FDA has approved dupilumab (Dupixent) as the first treatment with an indication for…

Physician’s Briefing Staff FRIDAY, Sept. 16, 2022 (HealthDay News) -- For children younger than 6 years, dupilumab significantly improves signs and…

PHOENIX -- Nearly three-fifths of patients with eosinophilic esophagitis (EoE) achieved remission after treatment with dupilumab…

PHOENIX -- Patients who received add-on dupilumab (Dupixent) treatment for chronic spontaneous urticaria (CSU) had reduced symptoms…

A new medication has been added to the treatment options for children with moderate-to-severe asthma. In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe…

Children with uncontrolled, moderate-to-severe asthma had better long-term lung function when they were treated with dupilumab…